Argus Lifts Merck to $145 After 1.2M Evaxion Stake

From a markets perspective, Merck's 1.2 million-share Evaxion position is financially immaterial, worth roughly $3.8 million, but strategically notable as optionality on a future vaccine franchise. Meanwhile, Argus's $145 target underscores that Merck's core earnings power remains the dominant market factor.

Merck & Company's August 10 regulatory disclosure that it holds 1,214,126 shares of Evaxion A/S is the latest signal that AI-driven vaccine discovery is moving from computational novelty toward pharmaceutical validation. Although the stake is worth only about $3.8 million at Evaxion's $3.17 early-trading price, a rounding error for a company with roughly $280 billion in market presence, the transaction sits alongside Merck's September 2025 decision to exercise an option to in-license EVX-B3, Evaxion's discovery-stage vaccine candidate aimed at an undisclosed bacterial pathogen. The combination of a direct equity position and a formal licensing option matters more than the dollar amount because it shows Merck is willing to attach both capital and pipeline rights to Evaxion's AI-enabled antigen discovery platform. Argus added to the positive backdrop on August 11 by raising its Merck price target from $130 to $145 with a Buy rating, citing regulatory approvals, clinical progress, M&A activity, pipeline depth, and a rising dividend.

“

Merck posted Q2 2026 revenue of $16.6 billion, up 5% year-over-year, driven by $8.4 billion from KEYTRUDA and $588 million from WINREVAIR.

The financials underscore two entirely different tiers of the biotech ecosystem. Merck posted Q2 2026 revenue of $16.6 billion, up 5% year-over-year, driven by $8.4 billion from KEYTRUDA and $588 million from WINREVAIR. Even as it reported a GAAP net loss of $1.335 billion, or $(0.54) per share, the loss was driven by a temporary $5.7 billion R&D charge from acquiring Terns Pharmaceuticals, and Merck simultaneously raised its full-year sales guidance to between $66.3 billion and $67.3 billion. Evaxion, by contrast, generated zero revenue in Q1 2026, reported a net loss of $3.6 million and loss per share of $(0.50), and must fund clinical trials and AI platform development through capital raises. The contrast is stark: one company can absorb a multi-billion-dollar acquisition charge and still raise guidance, while the other is betting its future on a single discovery-stage asset and the credibility of its AI platform.

For Evaxion, the Merck relationship is both validation and a potential financing lifeline. A micro-cap biotech with no revenue and ongoing cash needs can point to a mega-cap partner holding a direct equity stake and licensing its AI-discovered antigens as evidence that the technology has real-world value. EVX-B3's undisclosed bacterial pathogen makes it difficult for outside investors to size the opportunity, but the fact that Merck exercised its option suggests company scientists saw enough in the AI-generated antigen designs to secure rights before clinical data emerged. If Evaxion later advances EVX-B3 toward an investigational new drug filing, the validation value could translate into easier access to capital and possibly additional partnership interest.

Yet the clinical reality remains sobering. EVX-B3 is discovery-stage, meaning it has not entered human trials. Most discovery-stage vaccine candidates never reach approval, and the undisclosed pathogen leaves investors unable to assess disease burden or market potential. Merck's limited equity stake functions like a call option: it preserves upside exposure while keeping downside contained. The structure is consistent with how large pharma companies increasingly engage early-stage AI biotechs, using small investments and option-based licenses to monitor scientific progress without committing large balance-sheet resources.